NasdaqGS - Nasdaq Real Time Price ? USD 4D Molecular Therapeutics, Inc. (FDMT) Follow Compare 8.58 +0.05 (+0.59%) At close: October 21 at 4:00 PM EDT 8.50 -0.08 (-0.93%) After hours: October 21 at 5:43 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Zacks ? 7 days ago OCUL FDMT +0.59% 4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner 4D Molecular Therapeutics (FDMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. Zacks ? 26 days ago FDMT +0.59% 4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentationEMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a poster presentation at the 2024 North American Cystic Fibrosis Conference (NACFC) i GlobeNewswire ? 28 days ago FDMT +0.59% 4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate 4D Molecular Therapeutics (NASDAQ:FDMT) stock is trading lower on Thursday after the company released interim follow-up data from the Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design. Robust and durable treatment burden reduction was observed in all PRISM populations studied with the planned Phase 3 dose of 3E10 vg/eye of 4D-150. 83% overall reduction in annualized injections, 52% received 0 or 1 injection, and 44% injection-free in Phase 1/2a Severe study compared to Phase 2b Broa Benzinga ? last month FDMT +0.59% 4D Molecular data ‘bode well’ for eye gene therapy, but shares fall Shares dropped by as much as one-quarter Thursday after the biotech shared longer-term results for a gene therapy it’s developing for wet AMD. BioPharma Dive ? last month FDMT +0.59% 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day 4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data In broad population (Phase 2b), 70% injection-free through 52 weeksIn severe population (Phase 1/2a), 83% overall reduction in annualized injections through 52 weeks 4D-150 continues to be safe and well tolerated with intraocular inflammation (IOI) profile numerically similar (2.8% transient 1+ vitreous cells) to approved GlobeNewswire ? last month FDMT +0.59% 4DMT Announces Presentations at Upcoming Retina Conferences EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the Retina Society 57th Annual Scientific Meeting being held in Lisbon, Portugal on September 15, 2024 and at the 24th EURETINA Congress being held in Barcelona, Spain on September 19, 2024. The Retina Soc GlobeNewswire ? last month FDMT +0.59% 4DMT to Participate in the 2024 Cantor Global Healthcare Conference EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference. Members of the management team will also be available for one-on-one meetings. 2024 Cantor Global Healthcare Conference P GlobeNewswire ? last month FDMT +0.59% 4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 Company to highlight 4D-150 product development strategy and Phase 1/2 PRISM clinical trial data in wet age-related macular degeneration (wet AMD), including longest available interim follow-up data Overview of the 4FRONT Phase 3 clinical trial program in wet AMD Corporate webcast to be held on September 18, 2024 at 4:15 p.m. ET and followed by live Q&A with senior Company leadership and retinal disease key opinion leader (KOL) panel, including Arshad M. Khanani, M.D., M.A., FASRS, Carl D. Regil GlobeNewswire ? last month FDMT +0.59% 4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner 4D Molecular Therapeutics (FDMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. Zacks ? last month FDMT +0.59% 4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Members of the management team will also be available for one-on-one meetings. H.C. Wainwright 4th Annu GlobeNewswire ? 2 months ago FDMT +0.59% 4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag 4D Molecular Therapeutics ( NASDAQ:FDMT ) Second Quarter 2024 Results Key Financial Results Revenue: US$5.0k (down 98... Simply Wall St. ? 2 months ago FDMT +0.59% 4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates 4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 12.50% and 99.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago FDMT +0.59% 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet age-related macular degeneration (wet AMD) population, which includes patients representative of the planned Phase 3 study population, affirming favorable safety profile and robust clinical activityStrengthened senior leadership team and announced formation of a world class Ophthalmology Advisory Board to drive late-stage development of 4D-150 in wet AMD and diabe GlobeNewswire ? 2 months ago FDMT +0.59% 4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board Dhaval Desai, PharmD, named as Chief Development Officer; will oversee late-stage Product Development, Medical Affairs, Scientific Communications, Regulatory and Quality operations; most recently SVP & Chief Development Officer at Iveric Bio where he led development and approval of IZERVAYChristopher Simms named as Chief Commercial Officer, effective September 25, 2024; will oversee Pre-commercial and Commercial organizations, pre-launch preparations and development; most recently SVP & Chief Co GlobeNewswire ? 2 months ago FDMT +0.59% 4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection rate; 93% of patients received 0 or 1 injection and 77% were injection-freeImprovement in mean best corrected visual acuity (BCVA) from baseline through Week 24 achieved at 3E10 vg/eye dose (+4.2 letters); dose response in favor of 3E10 vg/eye dose demonstrated (+5.7 letters vs low dose)3E10 vg/eye dose demonstrated sust GlobeNewswire ? 3 months ago FDMT +0.59% 4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last? 4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Zacks ? 3 months ago FDMT +0.59% DERM 4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock? We recently compiled a list of the 10 Most Shorted Stocks That Are Loved by Analysts. In this article, we are going to take a look at where 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) stands against the other shorted stocks that are loved by analysts. Short selling is one of the more controversial ways of making […] Insider Monkey ? 3 months ago FDMT +0.59% 4D Molecular Therapeutics Says US FDA Clears its IND Application for Potential Geographic Atrophy Treatment 4D Molecular Therapeutics Says US FDA Clears its IND Application for Potential Geographic Atrophy Treatment PREMIUM MT Newswires ? 3 months ago FDMT +0.59% 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy 4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H (sCFH)Complement factor H (CFH) variants with reduced function are a well-validated genetic risk factor for geographic atrophy (GA), with approximately 75% of age-related macular degeneration (AMD) patients carrying a high-risk variant of CFHOver 150 patients have been treated with the R100 vector, including those with wet GlobeNewswire ? 3 months ago FDMT +0.59% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return FDMT S&P 500 YTD -57.65% +22.73% 1-Year -15.22% +38.58% 3-Year -72.02% +29.05%
